Keywords: cost-effectiveness, copd, combination, therapies, inhaled, steroids, long-acting

Cost-effectiveness of COPD combination therapies

Article | 07 June 2004

Print This

A combination of inhaled steroids and a long-acting beta 2 agonist is a cost-effective way to preserve lung function in patients ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in